Notes
HPRA = Health Products Regulatory Authority
Reference
Health Products Regulatory Authority. Aimovig (erenumab) - Risk of serious hypersensitivity and anaphylaxis, and updates regarding the risk of constipation. Internet Document : [1 page], 15 Oct 2020. Available from: URL: https://www.hpra.ie/docs/default-source/default-document-library/hpra-oct-2020---main-book_aimovig.pdf?sfvrsn=0
Rights and permissions
About this article
Cite this article
Erenumab labelling now includes serious hypersensitivity, constipation. Reactions Weekly 1828, 1 (2020). https://doi.org/10.1007/s40278-020-85077-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-020-85077-z